Phone -
Survival of patients with B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) has significantly improved over the last decade. The introduction of CD19-targeted CAR T-cell therapy has been a major breakthrough for salvaging patients with refractory disease. While most patients achieve a complete remission with this therapy, relapses are still observed. In my role as analyst within the Nierkens group, I provide essential support in preclinical research that is revolved around understanding the intricate network of factors that determine the success of this therapy. This knowledge will aid us in developing more effective therapies with which we can reach our goal to cure all patients with an optimal quality of life.